1. Home
  2. EFT vs CKPT Comparison

EFT vs CKPT Comparison

Compare EFT & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EFT
  • CKPT
  • Stock Information
  • Founded
  • EFT 2004
  • CKPT 2014
  • Country
  • EFT United States
  • CKPT United States
  • Employees
  • EFT N/A
  • CKPT N/A
  • Industry
  • EFT Finance Companies
  • CKPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • EFT Finance
  • CKPT Health Care
  • Exchange
  • EFT Nasdaq
  • CKPT Nasdaq
  • Market Cap
  • EFT 312.3M
  • CKPT 335.9M
  • IPO Year
  • EFT N/A
  • CKPT 2017
  • Fundamental
  • Price
  • EFT $12.07
  • CKPT $4.17
  • Analyst Decision
  • EFT
  • CKPT Buy
  • Analyst Count
  • EFT 0
  • CKPT 3
  • Target Price
  • EFT N/A
  • CKPT $4.33
  • AVG Volume (30 Days)
  • EFT 100.8K
  • CKPT 1.1M
  • Earning Date
  • EFT 01-01-0001
  • CKPT 05-16-2025
  • Dividend Yield
  • EFT 10.63%
  • CKPT N/A
  • EPS Growth
  • EFT N/A
  • CKPT N/A
  • EPS
  • EFT 1.73
  • CKPT N/A
  • Revenue
  • EFT N/A
  • CKPT $41,000.00
  • Revenue This Year
  • EFT N/A
  • CKPT $102,182.93
  • Revenue Next Year
  • EFT N/A
  • CKPT $351.71
  • P/E Ratio
  • EFT $7.62
  • CKPT N/A
  • Revenue Growth
  • EFT N/A
  • CKPT N/A
  • 52 Week Low
  • EFT $11.10
  • CKPT $1.47
  • 52 Week High
  • EFT $13.44
  • CKPT $4.50
  • Technical
  • Relative Strength Index (RSI)
  • EFT 49.84
  • CKPT 71.99
  • Support Level
  • EFT $11.99
  • CKPT $4.02
  • Resistance Level
  • EFT $12.15
  • CKPT $4.17
  • Average True Range (ATR)
  • EFT 0.12
  • CKPT 0.03
  • MACD
  • EFT 0.04
  • CKPT -0.01
  • Stochastic Oscillator
  • EFT 69.79
  • CKPT 93.33

About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest

Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Share on Social Networks: